---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Incidence"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Incidence. Topics: United States commercial, Medicaid, and Medicare claims: incidence by operating definition; United States commercial claims: progression to TRD within 1 year of newly treated depression; United States commercial claims: treated depressive episodes meeting TRD criteria; United States commercial claims: treated MDD meeting TRD criteria during follow-up; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/incidence"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Treatment-resistant depression

<a id="topic-2.2.1.2.1-1"></a>

### United States commercial, Medicaid, and Medicare claims: incidence by operating definition

| Database | Cap on time for a regimen to fail | Number of cases | Incidence estimate | Incidence 95% CI |
| --- | --- | --- | --- | --- |
| CCAE | 3 months | “4,791” | “33.93” | “32.97, 34.89” |
| MDCD | 3 months | “661” | “65.71” | “60.71, 70.72” |
| MDCR | 3 months | “228” | “13.08” | “11.39, 14.78” |
| CCAE | 6 months | “7,130” | “50.49” | “49.33, 51.65” |
| MDCD | 6 months | “987” | “98.12” | “92.01, 104.24” |
| MDCR | 6 months | “320” | “18.36” | “16.36, 20.37” |
| CCAE | 24 months | “9,038” | “64.00” | “62.69, 65.32” |
| MDCD | 24 months | “1,209” | “120.20” | “113.43, 126.96” |
| MDCR | 24 months | “404” | “23.19” | “20.93, 25.45” |

Source: [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/)

> “Incidence/100,000 cohort members/year.”
> “Truven MarketScan Commercial Claims and Encounters (CCAE), with approximately 35 million mainly privately insured subscribers in 2011; Truven MarketScan Medicaid (MDCD), a means-tested public insurance program with approximately 5 million subscribers in 2011, and Truven MarketScan Medicare Supplemental Beneficiaries (MCDR), a public insurance program that is not means-tested, with approximately 3 million subscribers in 2011, most of whom were aged 65 or older.”
> “we defined TRD as failure of two medications as evidenced by their replacement or supplementation by other medications, and set maximum durations (caps) for how long a medication regimen could remain in use and still be eligible to fail.”
> “TRD incidence estimates varied approximately 2-fold between the two databases (CCAE, Medicaid) that described socioeconomically different non-elderly populations; for a given cap varied 2-fold to 4-fold within each database across the other implementation choices; and if the cap was also allowed to vary, varied 6-fold or 7-fold within each database.”
> “among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that included a wider range of depression diagnoses among the PTD subjects”

Source: [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/)

<a id="topic-2.2.1.2.1-2"></a>

### United States commercial claims: progression to TRD within 1 year of newly treated depression

> “The outcome was TRD, defined as having at least three distinct antidepressants or one antidepressant and one antipsychotic within 1 year after the index date.”
> “Of 230,801 included patients, 10.4% developed TRD within 1 year.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.2.1-3"></a>

### United States commercial claims: treated depressive episodes meeting TRD criteria

> “Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD.”
> “Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year.”

Source: [Kubitz et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799999/)

<a id="topic-2.2.1.2.1-4"></a>

### United States commercial claims: treated MDD meeting TRD criteria during follow-up

> “Patients who started a third AD regimen after two regimens of appropriate duration were included in the TRD cohort.”
> “Out of 355,942 patients with MDD, 34,176 (9.6%) met the criterion for TRD.”

Source: [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/)

<a id="topic-2.2.1.2.1-5"></a>

### Sweden, Stockholm region: depressive episodes progressing to TRD

> “A total of 158 169 unipolar MDD episodes (in 145 577 patients) were identified between January 1, 2012, and December 31, 2017 (64.7% women; median [IQR] age, 42 years [30-56]). Of these, 12 793 episodes (11%) fulfilled criteria for TRD.”
> “The median (IQR) time from the start of MDD episode to TRD was 552 days (294-932).”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.2.1-6"></a>

### France, national claims sample: annual incidence and prevalence

> “Annual incidence and prevalence of TRD were estimated at 5.8 and 25.8 per 10 000 patients, respectively and at 7.8 and 37.6 per 10 000 patients, respectively in the sensitivity analysis.”

Source: [Bosco-Lévy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767421/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
